momentum 3 continued access protocol

Conditions: Advanced Refractory Left Ventricular Heart Failure

Summary: the objective of the study is to continue to evaluate safety and clinical performance of the hm3 lvas for the treatment of advanced, refractory, left ventricular heart failure following completion of enrollment in the the momentum 3 ide study.

enrollment in the cap cohort ended shortly after approval for the long-term indication was received from the fda in october 2018. as a condition of approval, all patients enrolled in the cap cohort were to complete the 2-year follow-up to fulfil a post-approval study requirement.

Eligibility criteria:
inclusion criteria: 1. subject or legal representative has signed informed consent form (icf) 2. age ≥ 18 years 3. bsa ≥ 1.2 m2 4. nyha class iii with dyspnea upon mild physical activity or nyha class iv 5. lvef ≤ 25% 6. a) inotrope dependent or b) ci \< 2.2 l/min/m2, while not on inotropes and subjects must also meet one of the following: * on optimal medical management (omm), based on current heart failure practice guidelines for at least 45 out of the last 60 days and are failing to respond * advanced heart failure for at least 14 days and dependent on intra-aortic balloon pump (iabp) for at least 7 days, 7. females of child bearing age must agree to use adequate contraception exclusion criteria: 1. etiology of hf due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, or restrictive cardiomyopathy 2. technical obstacles which pose an inordinately high surgical risk, in the judgment of the investigator 3. existence of ongoing mechanical circulatory support (mcs) other than iabp 4. positive pregnancy test if of childbearing potential 5. presence of mechanical aortic cardiac valve that will not be either converted to a bioprosthesis or oversewn at the time of lvad implant 6. history of any organ transplant 7. platelet count \< 100,000 x 103/l (\< 100,000/ml) 8. psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and lvas management 9. history of confirmed, untreated abdominal aortic aneurysm (aaa) \> 5 cm in diameter within 6 months of enrollment 10. presence of an active, uncontrolled infection 11. intolerance to anticoagulant or antiplatelet therapies or any other peri/post-operative therapy that the investigator will require based upon the patients' health status 12. presence of any one of the following risk factors for indications of severe end organ dysfunction or failure: * an inr ≥ 2.0 not due to anticoagulation therapy * total bilirubin \> 43 umol/l (2.5 mg/dl), shock liver, or biopsy proven liver cirrhosis * history of severe chronic obstructive pulmonary disease (copd) defined by fev1/fvc \< 0.7, and fev1 \<50% predicted * fixed pulmonary hypertension with a most recent pvr ≥ 8 wood units that is unresponsive to pharmacologic intervention * history of stroke within 90 days prior to enrollment, or a history of cerebrovascular disease with significant (\> 80%) uncorrected carotid artery stenosis * serum creatinine ≥ 221 umol/l (2.5 mg/dl) or the need for chronic renal replacement therapy * significant peripheral vascular disease (pvd) accompanied by rest pain or extremity ulceration 13. patient has moderate to severe aortic insufficiency without plans for correction during pump implant 14. pre albumin \< 150 mg/l (15mg/dl) or albumin \< 30g/l (3 g/dl) (if only one available); pre albumin \< 150 mg/l (15mg/dl) and albumin \< 30g/l (3 g/dl) (if both available) 15. planned bi-vad support prior to enrollment 16. patient has known hypo or hyper coagulable states such as disseminated intravascular coagulation and heparin induced thrombocytopenia 17. participation in any other clinical investigation that is likely to confound study results or affect the study 18. any condition other than hf that could limit survival to less than 24 months 19. patients actively listed for heart transplant (this exclusion applies only after commercial approval of the hm3 for short-term use)

Keywords: heart failure lvas ventricular dysfunction cardiomyopathy heart disease cardiovascular disease heart-assist devices thoratec corporation